Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION In a mid-size sponsor after a complete response letter, phase-3 protocol with endpoint-sensitivity issues is the evidence after a CMO 483 that maps to the NDA CMC module. Pharmacovigilance medical reviewer has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways close using phase-3 protocol with endpoint-sensitivity issues.

DECISION Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using phase-3 protocol with endpoint-sensitivity issues after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. Phase-3 protocol with endpoint-sensitivity issues reads as Proceed under protocol once a CMO 483 that maps to the NDA CMC module is lined up to the same Pharma & Life Sciences population. 2. Phase-3 protocol with endpoint-sensitivity issues is closer to Pause the pathway after a CMO 483 that maps to the NDA CMC module; Proceed under protocol would over-claim this CMC and Development Pathways extract. 3. Escalate safety review is still live in phase-3 protocol with endpoint-sensitivity issues for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter. 4. Phase-3 protocol with endpoint-sensitivity issues is missing the fact pharmacovigilance medical reviewer needs after a CMO 483 that maps to the NDA CMC module; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on the 505(b)(2) bridge is. 2. Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim pharmacovigilance medical reviewer would keep. 3. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read phase-3 protocol with endpoint-sensitivity issues against a CMO 483 that maps to the NDA CMC module and write the one fact that would move the 505(b)(2) bridge is for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (phase-3 protocol with endpoint-sensitivity issues after a CMO 483 that maps to the NDA CMC module). Lead with the Pharma & Life Sciences option phase-3 protocol with endpoint-sensitivity issues can support after a CMO 483 that maps to the NDA CMC module, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter.